$AFYA

Afya Ltd

Insider trades

No enriched coverage for $AFYA in the last 7 days.

No SEC Form 4 filings for $AFYA in the last 30 days.

See all $AFYA insider activity →

AFYA sentiment & insider activity

Recent AFYA coverage spans financial news and insider activity.

What's driving AFYA

  • Board committee chair change is governance-related and may modestly affect perceived oversight quality, but it is not a fundamental operating update.

    wallstreet-online.de · Jul 30, 2026

  • This is a routine insider sale with no stated 10b5-1 plan; it may slightly affect sentiment but is unlikely to change fundamentals.

    SEC EDGAR · Jul 6, 2026

  • Routine insider selling disclosed via Form 4; it may slightly affect sentiment but provides no new operating or financial catalyst.

    SEC EDGAR · Jun 30, 2026

  • Routine insider selling under a Form 4; likely limited incremental signal versus broader fundamentals.

    SEC EDGAR · Jun 30, 2026

  • JPMorgan Chase & Co. has lowered its price target for Afya from $22.00 to $21.50 while maintaining a 'neutral' rating. The new target indicates a potential upside of approximately 49.20% from the current price, suggesting moderate positive sentiment but with caution due to the unchanged rating.

    MarketBeat · Apr 30, 2026

alphai scores every news story that mentions AFYA with an AI model for sentiment and relevance, and aggregates insider trades from Afya Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AFYA

Score
$AFYAMed

JPMorgan Chase & Co. Cuts Afya (NASDAQ:AFYA) Price Target to $21.50

JPMorgan Chase & Co. has reduced its price target for Afya (NASDAQ:AFYA) from $22.00 to $21.50, maintaining a "neutral" rating. This new target suggests a potential upside of 49.20% from the stock's current price. Other analysts have also recently commented on Afya, with one strong buy rating, one buy rating, and six hold ratings, resulting in a consensus "Hold" rating and a price target of $17.20.

$AFYALow

Afya (AFYA) VP legal executes open-market sale of 5,000 shares

Anibal Jose Grifo de Sousa, VP Legal, Compliance and Government Relations at Afya Ltd (AFYA), sold 5,000 Class A Common Shares in an open-market transaction on April 7, 2026, at $15.20 per share. Following this sale, he retains direct ownership of 45,000 Class A Common Shares, indicating a continued significant stake in the company. The transaction was filed as a Form 4, providing transparency into insider trading activity.

$AFYALow

Afya (AFYA) CEO trims holdings with 1,810-share open-market sale

Afya Ltd CEO Gibbon Virgilio Deloy Capobianco reported selling a total of 1,810 Class A Common Shares in open-market transactions on March 27 and March 30, 2026. The sales were made at prices of $15.00 and $14.91 per share, respectively. Following these transactions, the CEO directly holds 151,938 Class A Common Shares and indirectly holds an additional 200,000 shares through GIBBOAT OVERSEAS LTD.

New Analyst Forecast: $AFYA Given $18 Price Target

UBS analyst Andre Salles has set an $18 price target for AFYA, aligning with the median target from three analysts over the last six months. Other analysts like Marcelo Santos (JP Morgan) and Leandro Bastos (Citigroup) have differing targets of $22 and $14, respectively. The article also notes recent institutional investor activity for AFYA stock, with some institutions increasing their positions and others decreasing them.

Related tickers